Early vaccine clinical studies on native-like envelope trimers and germline-targeting immunogens
03 February 2021
•
SY07
•
16:15
>
17:15
•
Early vaccine clinical studies on native-like envelope trimers and germline-targeting immunogens
•
Live channel 2
As a result of several important discoveries and structure-based design efforts, the first prototype immunogens to induce neutralizing antibodies have entered phase I clinical trials in 2019 and 2020. This session will cover the design and early results of several of these first-in-human vaccine studies. The tested immunogens include stable native-like trimers and germline-targeting immunogens, and represent promising components of vaccine regimens that induce broadly neutralizing antibodies.
16:15
•
SY07.01
•
Germline-targeting of the CD4 bindings site by eOD-GT8
See abstract
16:25
•
SY07.02
•
Fusion peptide epitope focused vaccines
See abstract
16:35
•
SY07.03
•
Immunogenicity of the prototype native-like trimer BG505 SOSIP.664
See abstract
16:45
•
SY07.04
•
Native-like trimers based on consensus and mosaic envelope sequences
See abstract
16:55
•
SY07.05
•
Germline-targeting by native-like envelope trimers
See abstract
17:05
•
SY07.06
•
Live Q&A
See abstract
|